BioSante Sees No Adverse Effect On LibiGel From Flibanserin Review
Executive Summary
The FDA advisory committee setback for Boehringer Ingelheim's hypoactive sexual desire disorder drug Girosa (flibanserin) has given a lift to BioSante Pharmaceuticals, which believes its testosterone gel LibiGel is now positioned to be the first approved treatment for HSDD
You may also be interested in...
Intrinsa Needs More Safety Studies In Face Of Potential Off-Label Use
Further safety studies of Procter & Gamble's testosterone patch Intrinsa are necessary prior to approval because of the potential for broad off-label use of the female sexual dysfunction therapy, FDA's Reproductive Health Drugs Advisory Committee said Dec. 2
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials